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Abstract
Delivery of tissue glues through small-bore needles or trocars is critical for sealing holes, affixing 
medical devices, or attaching tissues together during minimally invasive surgeries. Inspired by the 
granule-packaged glue delivery system of sandcastle worms, we have developed a nanoparticulate 
formulation of a viscous hydrophobic light-activated adhesive based on poly(glycerol sebacate)-
acrylate. Negatively charged alginate was used to stabilize the nanoparticulate surface to 
significantly reduce its viscosity and to maximize injectability through small-bore needles. The 
nanoparticulate glues can be concentrated to ~30w/v% dispersions in water that remain localized 
following injection. With the trigger of a positively charged polymer (e.g., protamine), the 
nanoparticulate glues can quickly assemble into a viscous glue that exhibits rheological, 
mechanical and adhesive properties resembling the native poly(glycerol sebacate)-acrylate based 
glues. This platform should be useful to enable the delivery of viscous glues to augment or replace 
sutures and staples during minimally invasive procedures.
Keywords
medical adhesive; nanoparticle; bio-inspired; sandcastle worm glue; injectability
1. Introduction
Methods to seal tissue leaks, attach devices, and to join tissues together during minimally 
invasive surgeries represents a significant challenge. Current surgical techniques that include 
sutures and staples are difficult to perform accurately through a narrow incision, do not 
provide a waterproof seal, and the materials used typically exhibit a mechanical mismatch 
with tissue and can cause tissue damage.[1–5] Tissue adhesives and sealants used in clinic 
include fibrin sealants (e.g., Tisseel™), cyanoacrylate-based glues (e.g., Histoacryl™, 
Dermabond™, Omnex™), and protein/peptide-based glues (e.g., BioGlue™, TissuGlu™), 
however their use in minimally invasive procedures is limited due to suboptimal usability/
controllability by surgeons as they are generally applied in a low viscosity state, are 
hydrophilic and can dilute in blood or other fluids, and it is typically difficult to control their 
adhesive activation. Furthermore, current tissue adhesives often do not exhibit the right level 
of adhesion in wet surgical fields and some exhibit toxicity for certain applications.[6–11] 
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Polymeric glues have been developed that are promising for use in minimally invasive 
procedures given their hydrophobic properties to repel tissue fluids at the target site, their 
viscosity to remain in place following delivery, and their light activated on-demand 
adhesion.[12] However, the viscosity can present challenges when delivery is required 
through small-bore needles, especially, during procedures such as endoscopic and 
laparoscopic surgeries and surgeries on fragile tissues within confined space (e.g. 
ophthalmic applications). A remaining challenge is to enable surgical adhesives to be 
delivered through narrow channels via introducer devices (e.g. endoscopes, laparoscopes, or 
syringe needles) with precise control over the amount and the application site of the surgical 
glues.[13] To maximize the injectability of glues, dilution using oils (e.g. lipiodol) or 
inclusion of low molecular weight monomers can be employed to reduce viscosities, yet are 
non-ideal given that the adhesion properties and amount of time required to activate 
adhesion are inevitably compromised and such approaches can increase potential 
toxicity.[14,15] As an alternative method, needle-free injection using jet injectors have been 
developed to deliver viscous fluids in a transdermal route without inducing skin 
lesions.[16–19] However, it is challenging to control the injection depth and this approach 
would be difficult to apply for minimally invasive internal procedures. There is an urgent 
need to develop approaches to enable the delivery of viscous medical adhesives through 
small-bore needles or trocars without compromising the adhesion force or safety.
Inspired by the viscous glue secretion mechanism of the sandcastle worm (Phragmatopoma 
californica), we have developed a nano-encapsulated viscous glue that can easily be injected 
through small-bore needles for application during minimally invasive procedures. Many 
marine species such as barnacles and marine mussels secrete high concentrations of protein 
glues into a mixing chamber where precursors are combined and are isolated from the 
surrounding environment.[20–27] This creates a unique plaque-and-thread structure that 
immobilizes the animal body to the substrate. In contrast, the sandcastle worms secrete glues 
into the surrounding environment without clogging their secretory ducts to build a tube-
shaped house that makes use of accessible particulates including sand particles.[28–31] To 
achieve this, high concentrations of proteinaceous glues are packaged into micrometer-size 
granules and stored in secretory cells (Figure 1a). When they are signaled to release the 
glues via a “burst” response, these granules are quickly delivered through secretory ducts 
into seawater that contains rich electrolytes and high pH (>8.0). The electrolytes in seawater 
trigger the granule membranes to rupture to release their glue contents resulting in viscous 
bulk glue mass that further cures to bond surrounding objects (e.g. sand particles). Inspired 
by the granule-based controlled glue transportation/activation system of sandcastle worms, 
we demonstrate a strategy to formulate viscous glues into water-dispersible injectable glue 
nanoparticles that can be assembled into the native viscous glue state following injection and 
can be cured in response to on-demand external stimuli (Figure 1b). As a model viscous 
water-insoluble glue, we used hydrophobic light-activating adhesive (HLAA).[12] HLAA is a 
polymeric UV-activated adhesive based on water-insoluble poly(glycerol sebacate)-acrylate 
(PGSA) polymer. Previously we showed that the glue could be delivered on a patch to a 
challenging target site (e.g., inside a beating heart) without washout where blood generates 
significant shear stress. HLAA is a viscous polymer system having viscosity more than 
50mPa.s that is generally regarded as the maximum viscosity of any liquid to be injectable 
Lee et al. Page 3
Adv Healthc Mater. Author manuscript; available in PMC 2016 November 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
through 27-gauge hypodermic needle (nominal inner diameter: 0.21mm), although this 
requires significant force. To develop an injectable formulation of HLAA, we coated viscous 
HLAA nanoparticles with a negatively charged water-soluble alginate that served to 
temporarily detackify the glue precursor (average diameter: 250–500nm). The injectability 
of the nanoparticle dispersions was studied and the reformulation of the nanoparticles into 
the native HLAA with a positive-charged polymer trigger was also investigated. To 
demonstrate the use of the nanoparticle glues in ophthalmic applications where surgical 
access is highly limited, intravitreal injection of the nanoparticle glue was evaluated for the 
potential application in retina repair.
2. Results and discussion
2.1. Fabrication of Stable HLAA Nanoparticles and Injectability
We envisioned that the ideal injectable nanoparticle HLAA (NanoGlue) should 1) have low 
resistance during injection through a small-bore needle, 2) be rapidly injectable within 
seconds, 3) not clog the needle during placement or injection, 4) be capable of rapid 
transition into a continuous mass after injection, 5) exhibit on demand curing as a single 
mass and 6) achieves the adhesion force of the native glue. To fabricate the viscous 
hydrophobic glue HLAA, PGSA (degree of acrylation: 0.5) was synthesized by acrylation of 
low moleculear weight poly(glycerol sebacate) (PGS, weight average molecular weight: 
5.0±0.4kDa) followed by the addition of a water-insoluble photoinitiator (0.2w/v% in 
HLAA) to avoid wash out in water (Figure 2a). In our previous study, the HLAA glue 
showed minimal inflammation and necrosis in animal models indicating the biocompatibility 
of the glue.[12] In a typical surgical scenario with HLAA, the viscous glue was placed 
manually (e.g. via a spatula). To transform the hydrophobic viscous liquid into non-tacky 
stable nanoparticles, negatively charged low viscosity alginate was selected as a candidate 
particle surface stabilizer (Figure 2b) based on its well-established biocompatibility. When 
the alginate molecules bind to the surface of the HLAA nanoparticles (potentially via 
physical adsorption), it was expected to lower the surface tension of the liquid to prevent 
them from rapid aggregation and phase separation. In addition, when the alginate-coated 
nanoparticles are exposed to oppositely charged substances, the highly negative surface 
charge from alginate promotes efficient agglomeration/transition from nanoparticles to bulk 
glue. To fabricate the HLAA nanoparticles coated with alginate (NanoGlue), HLAA 
(100mg) was dissolved in acetone (10ml) and added into an alginate solution in water (20ml, 
pH 7.0) drop wise with homogenization for 5 min followed by overnight evaporation of 
acetone and three centrifuge/dispersion cycles for purification. The resultant NanoGlue 
particles had average particle sizes of 267.7±36.9nm (fabricated in 0.1w/v% sodium 
alginate) and 408.2±25.1nm (fabricated in 0.5w/v% sodium alginate) measured by dynamic 
light scattering (DLS). The NanoGlue nanoparticles fabricated with the sodium alginate 
concentration higher than 0.1w/v% could be dispersed in distilled water or PBS (pH 7.4) and 
remain stable at 4°C for at least 2 weeks without any noticeable change in the average size 
measured by DLS. The NanoGlue particles fabricated with 0.02w/v% sodium alginate 
initially formed nanoparticles with the diameter of 150.8±54.6nm, but quickly formed a 
viscous aggregation on the bottom of a container within 3 days suggesting the there was an 
insufficient amount of alginate emulsifier on the surface of the NanoGlue. The zeta 
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potentials of the NanoGlues fabricated with 0.02, 0.1, and 0.5w/v% sodium alginate were 
−11.8±2.4mV, −50.0±4.0mV, and −48.8±5.3mV, respectively, indicating that the alginate 
coating is saturated at 0.1w/v%. This is also consistent with improved stability of the 
NanoGlue particles with 0.1, and 0.5w/v% alginate compared to the particles fabricated with 
lower 0.02w/v% alginate. Therefore, NanoGlue particles fabricated with 0.1w/v% sodium 
alginate solution were used in all the further studies.
To evaluate the force that the surgeons would experience to inject NanoGlue particle 
dispersions through a narrow needle, we loaded HLAA or NanoGlue dispersions (1.8w/v%, 
and 3.5w/v%) into a 1ml syringe attached with a 27g 1/2" syringe (inner diameter: 
0.210mm, length: 0.5 inch), and measured the force required to achieve a pre-determined 
flow rate (0.18, 0.36, 0.72, and 1.44ml/min) during the injection (Figure 3a). When the 
native HLAA was injected, high resistance was observed in low injection velocity, and in 
higher injection velocities above 0.36ml/min the force exceeded the technical limit of the 
force sensor (>50N). Considering that the typical hypodermic injection technique takes less 
than a minute to inject 1ml of water using 27g needles, the HLAA can be regarded as non-
injectable through 27g needles. In contrast, when the syringe was loaded with the 1.8 or 
3.5w/v% NanoGlue dispersions, there was low resistance at higher injection speed of 0.72 
mL/min and 1.44ml/min. The forces required to inject the NanoGlue dispersions at the rate 
of 0.72ml/min were 1.63 ± 0.16N for 1.8w/v% dispersions and 3.23 ± 0.19N for 3.5w/v% 
dispersion that were significantly lower than the native HLAA (exceeded sensor limit of 
50N) and were similar to the injection force of water (1.83 ± 1.08N). In minimally invasive 
procedures such as intraocular glue injection for retina repair and endoscopic surgeries using 
narrow bore injection devices, injection of glues into aqueous environment is desired (e.g. 
vitreous, stomach wall) without clogging the needle.[32,33] When the NanoGlue dispersions 
were injected into pH 7.4 PBS buffer (injection speed: 0.36ml/min, Figure 3b), the injection 
forces (2.70 ± 0.52N for 3.5w/v% NanoGlue and 1.96 ± 0.41N for 1.8w/v% NanoGlue) 
were similar to the forces required to inject water into pH 7.4 PBS (1.64 ± 0.36N) and also 
similar to the forces when they were injected into open air as shown in Figure 3a. However, 
cyanoacrylates, one of the primary adhesives considered in clinical practice that require 
injection through narrow channels (e.g., gastric varices treatment, ophthalmic 
surgeries)[10,15,33–35], can be non-specifically activated when they are exposed to an aqueous 
environment and potentially clog the tip of the needles or endoscopic channels (e.g., gastric 
varices repair).[33,36] When Dermabond™ in its inactive form was injected into pH 7.4 PBS, 
the injection force was moderately higher than the force to inject water or NanoGlue 
dispersions (5.27 ± 1.11N). When the activator was added to Dermabond™ as recommended 
by manufacturer and injected using the same method, it quickly formed a stiff glue residue at 
the tip of the needle during injection (Figure 3c) and the injection force was rapidly 
increased up to 33.94 ± 8.80N.
To maximize the concentration of the NanoGlue for rapid transformation upon exposure 
with positive charged substance, the correlation between NanoGlue concentration and 
injectability was investigated. A semiempirical model of Krieger and Dougherty describes 
that particle crowding enhances hydrodynamic interactions between particles, resulting in 
significant increase in viscosity with a relatively small increment of particle concentration: 
ηr = (1−ϕ/ϕm eff) −2, where ηr is the relative viscosity, ϕ is the volume fraction, and ϕm eff is 
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the effective maximum packing fraction.[37,38] Therefore, when NanoGlue concentration is 
increased, it is expected that 1) the viscosity would steeply increase, and 2) the NanoGlue 
dispersion would behave like a single-phase liquid as the interaction between particles 
increases. First, to develop the correlation between the NanoGlue particle concentration and 
the viscosity, dynamic viscosities of NanoGlue dispersions with different concentrations (0.1 
– 30w/v%) were measured using a rheometer. The viscosity of NanoGlue steeply increased 
as a function of concentration up to 38.9 ± 3.0mPa.s in 30w/v% (the maximum 
concentration that the NanoGlue dispersion could reach: 38.5w/v%) (Figure 3c), and the 
correlation was well fitted to the Krieger and Dougherty model with the maximum packing 
fraction ϕm eff =0.37 (r2=0.89) (Figure 3d). Considering that 50mPa.s is usually considered 
as the upper limit of injection using 25- to 27-g needles (red dashed line in Figure 3c), the 
30w/v% NanoGlue dispersion is in the injectable viscosity range. To demonstrate the 
behavior of NanoGlue dispersions in aqueous solutions, the NanoGlue dispersions with high 
particle concentration (30w/v%) close to maximum packing density and low particle 
concentration (3.7w/v%) were injected into pH 7.4 PBS. The high concentration NanoGlue 
dispersion flocculated as a separate phase in PBS (Figure 3e, Movie S1) due to the 
substantial interaction between the particles, but when in low concentration, the particles 
dispersed into PBS (Figure 3f, Movie S2). This single-phase behavior was observed only 
near the effective maximum packing fraction (i.e. 30w/v%) where the particle-to-particle 
interaction is the highest. This single-phase behavior of the high concentration NanoGlue 
dispersion is beneficial for medical applications (e.g., intraocular injection targeting the 
retina surface) because the dispersion could remain at the injection site before activation 
without dilution even on tissues submersed in water (e.g. vitreous), thus maximizing the 
interaction with tissue when it is cured.
To further assess the injectability of the high concentration dispersions with increased 
viscosity, the time required to draw 1ml of NanoGlue dispersions with different 
concentrations (0.1 – 30w/v%) using 27g 1/2” hypodermic needles was measured. In each 
experiment, the tip of the needle attached on a 1ml syringe was dipped into the dispersion 
vertically and the plunger was quickly pulled up to 1ml and the time required to draw 1ml 
was measured. NanoGlue dispersions could be easily drawn in ~10 seconds for 10w/v% 
NanoGlue dispersions (Figure 3g). The 1ml 30w/v% NanoGlue dispersion could be fully 
drawn in 31.5 ± 2.9 seconds. Considering glues are usually applied as a thin layer and the 
amount required to achieve adhesion is minimal (e.g., a few drops of glue dispersion with 
total volume of less than 0.1ml are required for ophthalmic applications)[10,39,40], it takes 
only a few seconds to apply 30w/v% NanoGlue dispersions to a target site. The native 
HLAA glue could not be drawn through the 27g 1/2” needles. Hagen-Poiseuille equation 
predicts the hydraulic flow behavior of viscous liquids generated from the pressure 
difference between each side of a narrow channel.[41–43] In the equation, viscosity is 
inversely correlated to the volumetric flow rate of the liquid: ΔP = 8μLQ/πr4, where ΔP is 
the pressure loss, L is the length of the needle, μ is the dynamic viscosity of the fluid, Q is 
the volumetric flow rate, and r is the radius of the needle. If we convert the volumetric flow 
rate Q (volume/time) to the time required to flow a fixed amount of liquid, the flow rate of 
NanoGlue can be fitted using the equation (r2=0.97) (Figure 3h) suggesting that the 
NanoGlue dispersions develop stable laminar (i.e. not turbulent) flow during injection and 
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the velocity is lower than the maximum threshold to generate turbulent flow (see also Figure 
3e and f, Movie S1 and Movie S2).
2.2. Reformulation of NanoGlue Particles into Viscous Glues with Similar Properties to 
Native HLAA Through Addition of Positively Charged Agents
In sandcastle worm glue granules, the surface charge of the granules across the granular 
membrane plays an important role in the membrane rupture and release of the glues from the 
granules. When sandcastle worms secrete glue granules into seawater, the high electrolyte 
concentration and high pH (>8) rapidly destabilizes the granule surface charge that was 
originally induced from the imbalanced equilibrium of charged substance across the 
membrane (i.e. Donnan equilibrium). This destabilization further initiates the membrane 
rupture to release the encapsulated glue components (e.g., mucin, Pc4, Pc3A,B) that rapidly 
coalesce into a continuous paste-like mass. We aimed to employ the external electrolyte-
initiated granular surface destabilization scheme of sandcastle worms to trigger the 
coalescence of NanoGlue particles by adding oppositely charged electrolytes. It was 
anticipated that for the NanoGlue particles the oppositely charged electrolytes (e.g., 
positively charged polymers) could neutralize the surface charge of the NanoGlue particles 
to initiate the coalescence. We chose protamine, a naturally derived arginine-rich protein 
(and has been used clinically to neutralize heparin with maximum dose of 50mg per 
injection at a concentration of 10mg/ml in 0.9w/v% normal saline) as a trigger for the 
NanoGlue coalescence process. To visualize the conversion from NanoGlue particles to bulk 
HLAA mass, fluorescence-labeled alginate (alginate-rhodamine) was used to fabricate 
fluorescent NanoGlue. Diluted fluorescence-tagged NanoGlue dispersion at a concentration 
of 1.8wt% was placed on a glass slide and combined with a protamine solution in water 
(0.5mg/ml). When the NanoGlue particles were added with water, the particles retain their 
size and shape without coalescence even though the particles constantly collided each other 
(Figure 4a, Movie S3) indicating that the surface charge from the alginate formed repulsive 
barriers around the NanoGlue particles. In contrast, as shown in Figure 4b and Movie S4, the 
addition of protamine induced the rapid coalescence of NanoGlue particles into micro-sized 
bulky masses (5–30 μm) indicating the repulsive barriers from alginate were neutralized to 
transform the particle surface more attractive to other particles. Scanning electron 
microscopy (SEM) images of the NanoGlue particles and the NanoGlue particles added with 
protamine also showed that the charge neutralization by protamine could also trigger 
stickiness of the particles to a given substrate. The particles without protamine maintain the 
spherical shape and high contact angle on a hydroxylated silicon wafer (Figure 4c), while 
the coalesced NanoGlue by addition of protamine spread with much lower contact angle 
(Figure 4d) indicating that protamine can trigger attraction (i.e. stickiness) of the NanoGlue 
to the hydroxlated silicon substrate. Within 2 minutes following the addition of 0.5mg/ml 
protamine solution, the average size of aggregates in the images was 15.4 ± 6.2μm (blue 
curve in Figure 4e). When lower concentration protamine solutions (0.1mg/ml and 
0.02mg/ml) were added into quiescent NanoGlue particles, the transitions were slower and 
the final aggregation sizes were smaller indicating that the transition rate depends on the 
protamine concentration. When higher concentration (30w/v%) NanoGlue dispersion 
(0.1ml) was added with 10mg/ml protamine solution (0.1ml), the originally turbid NanoGlue 
dispersion was cleared up in less than 5 seconds forming a sticky and viscous mass that is 
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phase-separated with aqueous dispersion similar to the original hydrophobic HLAA glue. 
The viscosity of the reformulated HLAA (14.6 ± 0.9 Pa.s) was also closely similar to the 
native HLAA (13.7 ± 1.1 Pa.s) (Figure 4f).
To further assess the curing properties of the reformulated HLAA, the reformulated glue was 
cured with UV exposure and the tensile strengths were measured using mechanical tester. 
The cured product of reformulated HLAA showed similar strain-stress curves to the cured 
native HLAA (Figure 4g). The average Young’s moduli were 1.74 ± 0.38 MPa and 1.43 
± 0.28 MPa for native HLAA and reformulated HLAA, respectively. The maximum strain at 
breaking was slightly lower for reformulated HLAA (42.3 ± 3.3 %) compared to the native 
HLAA (32.8 ± 3.1 %). It seems that during the transition of NanoGlue particles into bulk 
viscous glue, trace amount of aqueous solution became entrapped in the glue in the form of 
small droplets that generate nano-pores upon curing. To compare the adhesion properties of 
the reformulated HLAA and the native HLAA on a wet tissue, each glue was placed on a 
UV-transparent and elastic poly(glycerol sebacate)-urethane (PGSU) patch and cured on a 
heart (epicardium) tissue for pull-off adhesion tests using mechanical tester. The adhesion 
force of reformulated HLAA on epicardium tissue (1.43 ± 0.30 N/cm2) was closely similar 
to the native HLAA (1.42 ± 0.34 N/cm2) (Figure 4h). In our previous study, the in vivo 
adhesion force of the native HLAA was sufficient to successfully close vascular defects and 
to attach an elastic patch inside a beating pig heart.[12] In the in vivo rat cardiac defect 
models, the native HLAA successfully sealed the defect for up to 6 months with minimal 
short-term and long-term inflammation. We also found that the adhesion force of HLAA was 
several fold higher than conventional tissue glues including fibrin glues (e.g., TissuSeal™) 
and cyanoacrylate glues (e.g., Dermabond™) applied in aqueous environments. FT-IR data 
(Figure S1) also showed that there is no apparent difference in chemical structure between 
the native HLAA and the reformulated HLAA from NanoGlue particles.
2.3. Injection of NanoGlue Particle Dispersions into Biological Tissues and in situ Rapid 
Transition into Sticky Glue for Potential Medical Applications
To demonstrate the potential use of NanoGlue system in medical applications, we first 
hypothesized that, when NanoGlue particles are injected into a porous tissue and 
immediately triggered to aggregate in situ, they could form bulk sticky masses that would 
not easily diffuse away from the injection site. To examine this hypothesis, low 
concentration NanoGlue dispersions (3.7wt% in water) that are prone to diffusion (see 
Figure 3f) were subcutaneously injected into mouse ears along with protamine (0.5mg/ml in 
pH 7.4 PBS) or pH 7.4 PBS (Figure 5a). To maximize the particle-to-glue conversion rate, a 
double barrel syringe that intermix the contents from each barrel in an extended mixing 
channel was used and a 27G 1/2” needle was fitted at the tip of the syringe (Figure 5b). 
Using a custom-built video-rate laser-scanning confocal microscope, the NanoGlue particles 
were visualized at the injection site 5 minutes after injection. When NanoGlue particles and 
PBS (pH 7.4) were co-delivered, NanoGlue particles migrated several hundred micrometers 
from the injection site (Figure 5c). When NanoGlue particles were co-injected with 
protamine solution (0.5mg/ml), the particles rapidly formed bulk masses with sizes of ~30–
100μm adjacent to the injection site (Figure 5d) indicating the NanoGlue particles were 
reformulated into sticky HLAA and remained localized at the injection site for 5 min.
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We further aimed to use the NanoGlue system in minimally invasive ophthalmic surgeries 
such as retina repair for proliferative viteroretinopathy (PVR) where intraocular glue 
injection through a narrow entry is required. Proliferative vitreoretinopathy (PVR) is a 
disease that develops as a complication of rhegmatogenous retinal detachment. PVR occurs 
in about 8–10% of patients undergoing primary retinal detachment surgery and prevents the 
successful surgical repair of rhegmatogenous retinal detachment. PVR can be treated with 
surgery to reattach the detached retina but the visual outcome of the surgery is very poor. 
Especially, current treatment options insert intraocular tamponade materials (e.g., silicone 
oils or long-acting gases) in vitreous near the diseased site to press the detached retina onto 
the RPE. However, they are strongly associated with severe complications (e.g., cataracts, 
glaucoma) and the patient compliance is sub-optimal given that the treatment requires a 
head-down position for weeks. To address this, recent studies have examined the utility of 
medical adhesives, however currently available tissue adhesives are potentially toxic (e.g., 
cyanoacrylate), exhibit low adhesion or require long times to cure (e.g., fibrin glues) which 
can lead to rapid diffusion of the glue into the surrounding vitreous.[34] Therefore, we 
envisioned the NanoGlue system could be useful as an intraocular injectable glue, given that 
is 1) injectable through a small-bore needle (i.e. 27g needles), 2) not easily washed away 
after particle aggregation, 3) able to attach strongly in wet environments, and 4) 
biocompatible. We hypothesized that NanoGlue particle dispersions could be injected into 
the subretinal region via an intraocular route and then quickly form the sticky and viscous 
reformulated HLAA. To visualize the NanoGlue particles and the reformulated HLAA, the 
base polymer PGSA was labeled using rhodamine-isocyanate resulting in visible red color 
under ambient light. The high concentration red NanoGlue particle dispersion (30w/v% in 
water) was drawn into a 1ml syringe with a 27g 1” needle, and the needle was inserted 
through the anterior part of sclera of a freshly harvested bovine eye. The needle was further 
maneuvered vertically until it reached the retinal side of the posterior eye, and ~0.1ml of the 
NanoGlue dispersion was injected. The 1ml syringe was then rapidly replaced with another 
1ml syringe containing 10mg/ml protamine solution in distilled water or PBS (pH 7.4), and 
~0.05ml of the protamine solution (or PBS) was injected onto the same site (total amount of 
protamine: 0.5mg). The eyes were dissected 5 mins following injection. When NanoGlue 
dispersion was injected followed by protamine solution, a red-colored mass of the 
reformulated HLAA was observed isolated on the tapetum lucidum that is located 
immediately behind the retina (Figure 5e). This may serve useful to reattach the retina on the 
posterior membrane of the eye. Five minutes after injection, the NanoGlue particles 
delivered with PBS (pH 7.4) either migrated into the vitreous (when delivered without 
protamine) or were found as a few small masses (with protamine delivery) on the tapetum 
lucidum (Figure 5f) suggesting that the protamine trigger is critical to prevent dilution of 
even high concentration NanoGlue dispersions (30w/v%).
3. Conclusion
In conclusion, we demonstrated a nanoparticulate formulation of a viscous hydrophobic 
light-activated adhesive (NanoGlue) inspired by the granule-packaged glue delivery system 
of sandcastle worms. Negatively charged alginate was used to stabilize the NanoGlue 
surface to significantly reduce its viscosity and to maximize injectability through small-bore 
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needles (i.e., 27g hypodermic needles). The nanoparticulate glues could be concentrated to 
~30w/v% dispersions in water that remained localized following injection. With the trigger 
of a positively charged polymer (e.g., protamine), the nanoparticulate glues could quickly 
coalesce into a viscous glue that exhibits rheological, mechanical and adhesive properties 
resembling the native poly(glycerol sebacate)-acrylate based glues. The nanoparticulate 
glues could be injected into model biological tissues through 27g needles and formed 
viscous glues on the site of injection with the protamine trigger. This platform should be 
useful to enable the delivery of viscous glues to augment or replace sutures and staples 
during minimally invasive procedures.
4. Experimental Section
Synthesis of HLAA
PGS prepolymer was synthesized using the polycondensation reaction between glycerol and 
sebacic acid. Briefly, 4.6g of glycerol and 10.3g of sebacic acid (equimolar amount) were 
added into a round-bottom flask and reacted in 120°C for 8 hrs in nitrogen environment and 
for 16 hrs in vacuum (~50mmHg). The resultant PGS prepolymer had molecular weight of 
5.0±0.4kDa, determined using gel permeation chromatography (Viscotek TDA 305 with 
Agilent 1260 pump and autosampler, Malvern Instruments). The PGS prepolymer was 
further conjugated with an acrylate moiety using acryloyl chloride. Briefly, 5g of PGS 
prepolymer and 5mg of 4-(dimethylamino)-pyridine (DMAP, 0.0445mmol) was dissolved in 
200ml of anhydrous dichloromethane. Acryloyl chloride (0.5mol per mol glycerol on PGS) 
and triethylamine (equimolar to acryloyl chloride) were added dropwise for 30 min in an ice 
bath and reaction was kept for 24 hrs in room temperature under a nitrogen environment 
with vigorous stirring. The resultant PGSA was purified using precipitation into ethyl 
acetate. HLAA was fabricated by adding 0.2w/v% photoinitiator Irgacure 2959 (BASF) into 
PGSA. To make fluorescent HLAA, rhodamine-isocyanate was added (0.01mol per mol 
glycerol on PGSA) and reacted overnight. Rhodamine-labeled PGSA was purified using 
precipitation into ethyl acetate and further added with 0.2w/v% photoinitiator Irgacure 2959 
to prepare fluorescent HLAA.
Fabrication of NanoGlue particles using a single emulsion and characterization of the 
morphology and viscosity
NanoGlue particles were prepared using single oil-in-water emulsion method using water 
and acetone. Briefly, 20ml of 0.02w/v%, 0.1w/v%, or 0.5w/v% sodium alginate (low 
viscosity, Sigma-Aldrich) solution in water (final pH adjusted to 7.0) was placed in a 50ml 
beaker and 10ml of 1% HLAA solution in acetone was added drop wise for 5 min with 
homogenization (Tissue Master 125). To fabricate fluorescent NanoGlue particles using 
fluorescent alginate, 0.1w/v% sodium alginate conjugated with rhodamine (50kDa, Creative 
PEGWorks) was used instead of sodium alginate. The resultant white suspension was further 
stirred (400 rpm) overnight in the dark to evaporate acetone. The product was centrifuged at 
14,000 rpm for 10 min and redispersed in water for three times to separate NanoGlue from 
the residual alginate, unencapsulated HLAA, and acetone. The hydrodynamic diameter and 
polydispersity of NanoGlue particles were measured using dynamic light scattering 
(Malvern Zetasizer Nano ZS90) in water. The product yield was 78% calculated using 
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lyophilized NanoGlue compared to the original HLAA input. To determine the maximum 
concentration of NanoGlue particles that can remain in suspension the purified NanoGlue 
suspension was centrifuged at 14,000 rpm for 10 min and the supernatant was carefully 
removed and the weight was measured. The concentrated NanoGlue dispersion was further 
lyophilized and the dry weight was measured. The maximum concentration of the NanoGlue 
dispersion was 38.5w/v%.
Measuring the force required to inject HLAA, NanoGlue, and cyanoacrylate through 27g 
needles
To measure the injection forces, each 1ml of HLAA, NanoGlue dispersion in different 
concentrations (1.8w/v% and 3.7w/v%), or Dermabond™ (Ethicon) with or without the 
activator was loaded within 1 ml plastic syringe (BD) with a 27g 1/2" needle (BD). To 
simulate the forces that would be applied by a surgeon, the syringe barrel was vertically 
fixed on a mount with the needle facing down and the plunger was pressed downward by a 
force sensor on a mechanical tester (ADMET) at different injection speeds (0.18, 0.36, 0.72, 
and 1.44 ml/min). To test the injection force into aqueous solutions, the needle was 
submerged in pH 7.4 PBS for 1 min and injected into the PBS. The applied forces were 
monitored by the software associated with the force sensor. Loading profiles were obtained 
and the maximum force acquired was quantified. Each experiment was repeated at least 3 
times.
Viscosity measurement of native HLAA glue and NanoGlue dispersions in different 
concentrations
Viscosities of HLAA and NanoGlue dispersions in different concentrations (0.1 – 30w/v%) 
in water were analyzed using a rheometer (AR-G2, TA Instruments). Dynamic viscosity of 
each liquid was measured using a 20-mm plate with 200-μm gaps (shear rate: 0.01–100 1/s 
in log scale, shear rate of 1 1/s was selected to compare viscosity of materials).
Measuring the time to draw 1ml of NanoGlue dispersions through 27g 1/2” 
needles—To assess the correlation between NanoGlue dispersion concentration and 
injectability, the time required to draw 1ml of NanoGlue dispersions with different 
concentration (0.1 – 30w/v%) using 27g 1/2” hypodermic needles were measured. In each 
experiment, the tip of the needle attached on a 1ml syringe was dipped into the dispersion 
vertically and the plunger was quickly pulled up to 1ml and the time required to draw 1ml 
was measured manually using an electronic timer.
Visualization of NanoGlue aggregation upon exposure to positive charged trigger using 
confocal microscopy
To visualize the aggregation of NanoGlue particles, low concentration NanoGlue dispersions 
(3.7w/v%) was placed onto a glass slide on the fluorescent confocal microscope (Perkin 
Elmer UltraView RS). Protamine solutions at different concentrations (0.02, 0.1, or 0.5 
mg/ml in water) were added to trigger particle aggregation. Images were acquired every 10 
seconds for 3 minutes and the size of the particles for each imaging area (0.0145mm2) were 
measured with ImageJ. To filter the background noise from the images, the contrast was 
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adjusted to obtain the sizes of less than 50 particles per imaging area. At least three 
randomly selected imaging spots were sampled.
Characterization of NanoGlue morphology change before and after the protamine 
treatment using scanning electron microscope (SEM)
To visualize the NanoGlue particles using SEM, the NanoGlue particle dispersion (3.7w/v% 
in water) was placed on an oxygen plasma-treated silicon wafer and air-dried. To visualize 
the reformulated HLAA by treating the NanoGlue particles with protamine, NanoGlue 
particle dispersion (3.7w/v% in water) mixed with the same amount of 0.5w/v% protamine 
solution in water was placed on an oxygen plasma-treated silicon wafer for 5 min, and 
further air-dried. The dried samples were sputter-coated with a 10 nm gold film and the 
particles were visualized via SEM (JEOL 6320 operated at 5kV).
Mechanical properties of reformulated HLAA and its cured product
To assess the mechanical strength of the reformulated HLAA after curing compared to the 
native HLAA, 30w/v% NanoGlue dispersion was mixed with 10mg/ml protamine solution 
for 1 min and the precipitated viscous sticky product was carefully collected. The viscous 
product and the native HLAA were cured with UV light (light intensity: 0.38 W/cm2) for 30 
seconds in 1mm thick sheets and cut using a dog bone-shaped punch for tensile testing. Each 
dog bone-shaped sample was immobilized using sample grips at both ends and pulled until 
break in a rate of 8mm/min. The applied force was monitored using a force sensor connected 
to the mechanical tester. Young’s moduli were calculated at 10% strain. Tests were 
performed in triplicate.
Measurement of the adhesion strength of native HLAA and HLAA NanoGlue particles
To compare the adhesion properties of the reformulated HLAA and the native HLAA on wet 
tissue, each glue was placed on a UV-transparent and elastic poly(glycerol sebacate)-
urethane (PGSU) patch and cured on heart (epicardium) tissue for pull-off adhesion tests 
using mechanical tester. Sliced tissue samples were fixed on standard SEM pin stub mount 
(Ø12.7mm × 8mm pin height, Ted Pella Inc) by instant glue (Loctite 495, Henkel) and 
wetted with PBS. PGSU films (100–200 μm thick) were prepared according to our published 
procedure and cut into round patches with the diameter of 6 mm. During the test, SEM pin 
stubs with tissue samples were loaded on the bottom stage of the mechanical tester 
(ADMET). Then, 50μl of 30w/v% NanoGlue particle dispersion (containing 0.2w/v% 
Irgacure 2959 in HLAA, total volume of HLAA: 13μl) was applied onto the tissue segment, 
and 50μl of 10mg/ml protamine solution (500μg in total) in PBS (pH 7.4) or 50μl of PBS 
(pH 7.4) was applied onto the same site. Thirteen microliter of native HLAA was placed on 
another tissue segment using a positive displacement pipette to compare the adhesion force. 
After 1 min of glue application, a 200μm thick PGSU film was placed on top of each glue 
application site. A UV light guide (Lumen Dynamics Group Inc.) was applied onto the 
PGSU film with UV transparent borosilicate glass as a non-adhesive spacer to facilitate the 
release of curing system (i.e. UV light guide and borosilicate glass) without disturbing the 
patch/adhesive-tissue interface. The glues were cured with UV light (light intensity: 0.38 
W/cm2) for 10 seconds with a compressive force of −3N. A metal probe with a diameter of 
5mm was attached onto the PGSU patch using instant glue (Loctite 495) and pulled off with 
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a constant strain of 8mm/min. The applied force was monitored and the maximum force 
before full detachment of the patch was measured as the adhesion force. All the experiments 
were performed in triplicate.
NanoGlue particle localization study in a mouse ear with intravital confocal microscopy
BALB/C mice (Charles River Laboratories, Wilmington, MA) were sacrificed immediately 
before injection and the hair around the base of both ears was trimmed with scissors. Double 
barrel syringe (Sulzer Mixpac USA, Inc. NH) was adjusted by connecting a 27G needle 
(BD) to the tip of mixer. Then, 3.7w/v% NanoGlue particle dispersions were co-delivered 
with the same amount of either protamine (0.5mg/ml) or PBS subcutaneously into the mouse 
ear with a double barrel syringe. Five minutes after the injection, the injection sites were 
imaged with a custom-built video-rate laser-scanning confocal microscope designed 
specifically for live animal imaging. To image the surrounding tissue, we positioned the 
mouse ear on a coverslip (with index matching gels) and obtained high-resolution images 
with cellular details through the intact mouse skin at depths of up to 250 μm. The laser 
beams were focused onto the sample (mouse ear skin) using a 60×, 1.2NA water immersion 
objective lens (Olympus, Center Valley, PA). Fifteen frames were averaged from the live 
video mode to improve the signal to noise ratio. Excitation of 480nm was used to induce 
green autofluorescence of mouse ear skin to indicate the location of the tissue matrix.
Ex vivo intraocular injection of NanoGlue particles
To visualize the NanoGlue particles, the rhodamine-labeled PGSA was used to fabricate 
HLAA and NanoGlue particles. The labeled NanoGlue particles showed visible red color 
under ambient light. High concentration red NanoGlue particle dispersion (30w/v% in 
water) was drawn into 1ml syringe with a 27g 1” needle, and the needle was inserted 
through the anterior part of sclera of a freshly harvested bovine eye (used within 3 days after 
harvesting). The needle was further maneuvered vertically until it reached the retinal side of 
the posterior eye, and ~0.1ml of the NanoGlue dispersion was injected. The 1ml syringe was 
then rapidly replaced with another 1ml syringe containing 10mg/ml protamine solution in 
distilled water or PBS (pH 7.4), and ~0.05ml of the protamine solution (or PBS) was 
injected onto the same site. The eyes were dissected after 5 mins of injection and the 
residual red NanoGlue particles were imaged using a personal use camera (iPhone6, Apple).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic representation of nanoparticulate glues (NanoGlue) inspired by the granule-
mediated glue transportation system of sandcastle worms. (a) Sandcastle worms condense 
high concentration proteinaceous glues into micron-sized granules to secret viscous glues 
through narrow secretory ducts. When the granules are secreted and exposed to the 
electrolyte-rich seawater, their membrane ruptures to release viscous glues. The glues 
aggregate into a bulk mass that further cures to attach surrounding objects. (b) Schematic 
representation of fabrication of the bioinspired injectable NanoGlue nanoparticles using 
alginate as a surfactant to encapsulate the hydrophobic viscous glue HLAA. When they are 
exposed to positive-charged trigger molecules, NanoGlue particles aggregate to form a 
viscous glue that is similar to the native HLAA.
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Figure 2. 
Synthesis of the hydrophobic viscous glue HLAA and fabrication of NanoGlue particles. (a) 
Synthesis scheme of the hydrophobic viscous glue HLAA. Glycerol and sebacic acid were 
polymerized using polycondensation reaction and further conjugated with acrylate groups to 
fabricate UV cross-linkable glue. Degree of acrylation was 0.5mole per 1 mole of hydroxyl 
groups in the polymer backbone. (b) Fabrication of NanoGlue nanoparticles using single-
emulsion method. The viscous HLAA was dissolved in acetone (10mg/ml) and added in 
0.1w/v% sodium alginate solution (pH adjusted to 7.0) with homogenization. After 
evaporation of acetone and purification using centrifugation/re-suspension cycles, the white 
turbid NanoGlue particle dispersions were formulated. (c) Size distribution of NanoGlue 
particles in aqueous solutions measured using dynamic light scattering (DLS). The 
NanoGlue particles were fabricated in sodium alginate solutions with three different 
concentrations (0.02, 0.1 and 0.5w/v%). The NanoGlue particles had average sizes of 
150.8±54.6nm, 267.7±36.9nm, and 408.2±25.1nm when fabricated in 0.02w/v% (red bars), 
0.1w/v% (blue bars), and 0.5w/v% (black bars) aqueous sodium alginate solutions, 
respectively. Due to the instability of NanoGlue particles fabricated with sodium alginate 
concentration less than 0.1w/v%, the NanoGlue particles fabricated in 0.1w/v% sodium 
alginate solution was used in all the further studies.
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Figure 3. 
NanoGlue particle dispersions at concentrations up to 30w/v% in water are injectable 
through 27g 1/2" needles. (a) Injection forces of native HLAA (black dots), 3.5w/v% 
NanoGlue dispersions (red dots), 1.8w/v% NanoGlue dispersions (purple dots), and water 
(blue dots) at injection speeds from 0.18 to 1.44 ml/min. The liquids were injected vertically 
into air. The injection force could not be measured with native HLAA at speeds over 0.36 
ml/min because it exceeded the detection limit of the force sensor (~50N). (b) Injection 
forces of native HLAA, NanoGlue dispersions (3.5w/v% and 1.8w/v% in water), water and 
Dermabond™ into pH 7.4 PBS. The injection speed was 0.36ml/min. Activated form of 
Dermabond™ partially clogged the tip of the needle during injection into PBS. (c) Viscosity 
of native HLAA and NanoGlue particle dispersions (0.1 – 30.0w/v% in water). The viscosity 
of ~50mPa.s is generally considered as injectable (red dashed line).[44][45] (d) Correlation 
between experimental volume ratios and relative viscosity of NanoGlue particle dispersions. 
Concentration of each sample is indicated in upper x-axis. The plot was fitted in the 
semiempirical model of Krieger and Dougherty that predicts the viscosity change of 
nanoparticle dispersions at different concentrations: ηr = (1−ϕ/ϕm eff) −2, where ηr is the 
relative viscosity, ϕ is the volume fraction, and ϕm eff is the effective maximum packing 
fraction. The ϕm eff was 0.37 (r2=0.89) indicating that the viscosity of NanoGlue dispersions 
would increase more drastically in volume fractions (i.e. volumetric concentrations) close to 
0.37 (42.6w/v% of NanoGlue dispersion). This was in good agreement with the maximum 
injectable concentration of ~30w/v% in Figure 3c. (e) Representative image of 30w/v% 
NanoGlue dispersions injected into pH 7.4 PBS. The NanoGlue dispersions were flocculated 
on the bottom of the vial as a separate phase liquid (i.e. without dispersion) (see also Movie 
S1) indicating that the 30w/v% NanoGlue dispersions would not easily diffuse into the 
surrounding environment. (f) Representative image of 3.7w/v% NanoGlue dispersions 
injected into pH 7.4 PBS. The NanoGlue dispersions were slowly dispersed into PBS (see 
also Movie S2). (g) Time to draw 1ml of native HLAA and NanoGlue dispersions (0.1 – 
30.0 w/v%) through 27g 1/2” needles. HLAA was unable to draw through the narrow 
needles. (h) Correlation between viscosity and time to draw 1ml of NanoGlue dispersions in 
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different concentrations (0.1 – 30.0 w/v%) through 27g 1/2” needles. To obtain the 
correlation coefficient (i.e. r2), the plot was fitted to Hagen-Poiseuille equation (blue dashed 
line): ΔP = 8μLQ/πr4, where ΔP is the pressure loss, L is the length of the needle, μ is the 
dynamic viscosity of the fluid, Q is the volumetric flow rate, and r is the radius of the needle.
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Figure 4. 
Assembly of NanoGlue particles with protamine into viscous glues exhibits similar 
properties to native HLAA. (a–b) Representative confocal fluorescent images of fluorescent 
NanoGlue particles on glass slides treated with (a) pH 7.4 PBS, or (b) 0.5mg/ml protamine 
solution in PBS (pH 7.4). The images were taken in 0, 30, 60 and 120 seconds after each 
solution was added. All scale bars indicate 5μm. (c–d) Scanning electron microscopy (SEM) 
images of NanoGlue particles treated with (c) pH 7.4 PBS, or (d) 0.5mg/ml protamine 
solution in PBS (pH 7.4). The scale bars indicate 10μm. (e) Change of NanoGlue particle 
size treated with protamine solutions (0.02, 0.1 and 0.5mg/ml). Average particle sizes were 
measured from images obtained using confocal microscopy. (f) Viscosity of native HLAA 
(white bar) and reformulated HLAA from NanoGlue particles (black bar). (g) Representative 
tensile stress-strain curves of cured HLAA (black line) and cured reformulated HLAA from 
NanoGlue particles (red line). The glues were cured under UV (0.38W/cm2 at 365nm 
wavelength for 10 seconds) in the thickness of 1.0mm and cut in dog bone shape for tensile 
tests. (h) Adhesion forces of native HLAA (white bar), 30 w/v% NanoGlue dispersions in 
water (blue bar), and reformulated HLAA from NanoGlue particles (red bar) on epicardium 
(heart) tissue.
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Figure 5. 
Injection of NanoGlue particle dispersions into biological tissues and in situ rapid transition 
into a viscous glue for potential medical applications. (a–d) To demonstrate the ability of the 
NanoGlue to reformulate in vivo, NanoGlue particles were injected into an ear of a balb/c 
mouse and immediately triggered for coalescence in situ. To inject NanoGlue particles, a 
double-barrel syringe equipped with a mixer and 27g 1/2” needle (b) was used. (c–d) A 
custom-built video-rate laser-scanning confocal microscope was used to image the particle 
distribution of (c) NanoGlue particles injected with PBS and (d) 3.7w/v% NanoGlue 
particles injected with 0.5mg/ml protamine solution in 5min after injections. The alginate on 
NanoGlue particles was labeled with rhodamine (red in the images in (c) and (d)). Green 
fluorescence is generated via the autofluorescence of mouse ear skin under an excitation of 
480nm. Yellow arrows indicate the injection sites. (e–g) Potential applications of NanoGlue 
system in minimally invasive ophthalmic surgeries such as retina repair for proliferative 
viteroretinopathy (PVR) where intraocular glue injection through a narrow entry is required. 
Representative images of 30w/v% NanoGlue dispersions injected with (f) 10mg/ml 
protamine solution in PBS (pH 7.4), or (g) pH 7.4 PBS. The eyes were dissected in 5min 
after injections. To visualize the NanoGlue particles and the reformulated HLAA, the PGSA 
polymer was labeled using rhodamine-isocyanate resulting in a visible red color under 
ambient light.
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